The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial.
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced the presentation of data from its Quinamed? (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors.
The investigational drug axitinib produced tumor regression or stable disease in almost three-out-of-four patients with advanced thyroid cancer, a research team reported June 3 at the annual meeting of the American Society for Clinical Oncology in Chicago.
A study, lead by Dr. Laura Rosi?ol, researcher of the Haematooncology Group of Hospital Cl?nic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations.
Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide — marketed as Trisenox — significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the impressive survival benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.
A study, led by Dr. Joan Blad?, researcher of the Haematooncology Group of Hospital Cl?nic-IDIBAPS (Barcelona), in collaboration with Dr. Laura Rosi?ol, researcher of the same group, assessed the efficiency in terms of response and survival of autologous bone marrow transplantation in patients suffering from refractory myeloma previously having undergone high-dose chemotherapy (HDT).
A clinical trial led and coordinated by Hospital Cl?nic-IDIBAPS, using a drug named Sorafenib, revolutionizes the reality of patients suffering from advanced liver cancer. The results increase overall survival of treated patients by 44 percent in comparison to the control group. The results have been hand selected to be included on the “Best of ASCO” program.
Bayer HealthCare, a subsidiary of Bayer AG (NYSE: BAY), and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar? (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%.
GlaxoSmithKline (NYSE: GSK) announced that the European Commission approved its novel topical antibacterial ALTARGO? (retapamulin ointment,1%) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds.